OCS
Oculis Holding AG
NASDAQ · Healthcare · Biotechnology · CH
$7.32
+0.41%Year over year
Reported trailing growth
- Revenue
- -6.9%
- EBITDA
- +26.3%
- EBIT
- -14.5%
- EPS
- +40.4%
- Free cash flow
- -13.0%
- Operating cash flow
- -15.6%
Forward estimates
Based on analyst estimates
- Revenue
- +105.5%
- EBITDA
- -25.0%
- EPS
- -16.0%
Three-year CAGR
- Revenue
- -100.0%
- EBITDA
- -9.1%
- EBIT
- -8.1%
- Net income
- -10.2%
- EPS
- +14.6%
- Free cash flow
- -31.0%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026